|
Rhegmatogenous retinal detachment
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Compared to controls, patients with PDR had significantly higher levels of thrombin-antithrombin III complex (p < 0.001), vascular endothelial growth factor (p < 0.001), D-dimer (p = 0.038) and interleukin-8 (p = 0.04), and patients with RRD group had significantly higher levels only of thrombin-antithrombin III complex (p < 0.001).
|
31833198 |
2019 |
|
Epithelial ovarian cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
ApoE multiplexed with EpCAM, plg, serpinC1 and C1q provide optimal diagnostic information for EOC with AUC = 0.913 (95% confidence interval (CI) =0.848-0.957, p < 0.0001).
|
31718609 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
ApoE multiplexed with EpCAM, plg, serpinC1 and C1q provide optimal diagnostic information for EOC with AUC = 0.913 (95% confidence interval (CI) =0.848-0.957, p < 0.0001).
|
31718609 |
2019 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There are however no current studies assessing the levels and activity of protein C (PC), protein S (PS), and antithrombin III (AT III), which are essential in haemostatic regulation, in a single cohort of T2DM patients.
|
31560710 |
2019 |
|
Endothelial dysfunction
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
ATIII plays a role in FFP-mediated protection of endothelial Sdc1 expression and barrier function, making it a potential therapeutic target to mitigate HS-induced endothelial dysfunction.
|
31389906 |
2020 |
|
Kidney Failure, Acute
|
0.050 |
Biomarker
|
disease |
BEFREE |
Cutoff values for these factors were calculated using ROC analyses, and the combination of ATIII and U-P/Cr, which were poorly correlated, was predictive of AKI.
|
31269838 |
2019 |
|
Cerebral Infarction
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |
|
Myocardial Infarction
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |
|
Acute myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |
|
Anterior myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
AMI complicated with cerebral infarction has negative correlations with the levels of AT-III and adiponectin, but positively associated with the levels of NT-proBNP, HOMA-IR and HMGB1, possessing certain clinical significance in AMI treatment.
|
31173318 |
2019 |
|
Antithrombin III Deficiency
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
A series of 10 Polish patients with thromboembolic events and antithrombin deficiency: two new c.1154-1 G>C and c.1219-534 A>G SERPINC1 gene splicing mutations.
|
31157679 |
2019 |
|
Liver diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Role of Both Protein C and Antithrombin III as Predictors of stage of liver disease in Chronic Viral Hepatitis B or C Infected patients.
|
31142255 |
2020 |
|
Chronic liver disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Antithrombin III and protein C are natural anticoagulants can be considered as markers of different stages of chronic liver disease.
|
31142255 |
2020 |
|
Hepatitis B, Chronic
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was the evaluation of protein C and antithrombin III in different stages of chronic hepatitis B and C and to determine their possible role as markers of liver cell damage in different clinical stages.
|
31142255 |
2020 |
|
Disseminated Intravascular Coagulation
|
0.330 |
Biomarker
|
disease |
BEFREE |
Anticoagulation Therapy Using rh-Thrombomodulin and/or Antithrombin III Agent is Associated With Reduction in in-Hospital Mortality in Septic Disseminated Intravascular Coagulation: A Nationwide Registry Study.
|
31090683 |
2019 |
|
Antithrombin III Deficiency
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Deep Vein Thrombosis
|
0.500 |
CausalMutation
|
disease |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Deep Vein Thrombosis
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Antithrombin III Deficiency
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Molecular basis of SERPINC1 mutations in Japanese patients with antithrombin deficiency.
|
31030036 |
2019 |
|
Deep Vein Thrombosis
|
0.500 |
Biomarker
|
disease |
BEFREE |
We investigated SERPINC1 defects in Japanese patients with congenital AT deficiency who developed venous thromboembolism or had a family history of deep vein thrombosis.
|
31030036 |
2019 |
|
Venous Thromboembolism
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We investigated SERPINC1 defects in Japanese patients with congenital AT deficiency who developed venous thromboembolism or had a family history of deep vein thrombosis.
|
31030036 |
2019 |
|
Endocarditis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Patients with endocarditis (N = 21), compared to controls (N = 21), presented lower antithrombin III at day 4 (p < 0.05), elevated antithrombin III at day 90 (p < 0.01), prolonged activated partial thromboplastin time at days 4 and 10 (p < 0.05), and enhanced thrombin-antithrombin complex at day 4 (p < 0.01).
|
31009118 |
2019 |
|
B-Cell Lymphomas
|
0.010 |
AlteredExpression
|
group |
BEFREE |
It was also demonstrated that silencing SERPINC1 upregulated the expression of B‑cell lymphoma-2 (Bcl‑2)‑associated X protein and p53 mRNA and protein, and downregulated that of Bcl‑2, survivin and cyclin D1.
|
30896875 |
2019 |
|
Nasopharyngeal carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
It was revealed that the expression levels of SERPINC1 mRNA and protein were increased in NPC tumor tissues compared with in adjacent healthy tissues.
|
30896875 |
2019 |
|
Exfoliation Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The concentration of complement factor 3, kininogen-1, antithrombin III and vitamin D-binding protein was increased in all eyes with PEX.
|
30842085 |
2019 |